FDA Grants Bionaut Labs Orphan Drug Designation to BNL-101 for the Treatment of Malignant Gliomas in Pediatric and Adult Patients

By June 24, 2021No Comments

The U.S. Food and Drug Administration (FDA) has granted Bionaut Labs orphan drug designation for BNL-101 for the local treatment of all malignant gliomas including diffuse intrinsic pontine glioma in pediatric and adult patients. BNL-101 is a drug-device combination comprised of doxorubicin as the active drug component together with the company’s Bionautâ„¢ microscale robots.